Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Adial Pharmaceuticals Inc

ADIL ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: BUY

Last Close

$3.98

▼ -9.34%

Market Cap $10.27M · Vol 15.76K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$10.27M

Micro Cap

Div Yield

N/A

EPS Growth

+73.62%

YoY

RSI (14)

66.12

Momentum

Beta

1.31

vs Market

52W High

$10.70

62.81% below

52W Low

$1.31

203.82% above

Volume

15.76K

Avg 14.56K

P/B

0.05

Price-to-book

ROE

N/A

Return on equity

Free Float

95.32%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Adial Pharmaceuticals Inc (ADIL) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does ADIL pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+0.00%

+50.19%

+192.65%

+39.65%

YTD

-27.64%

-59.65%

-95.84%

-99.81%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-7,977,170.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-136.16% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	0.05
P/FCF	N/A
EPS Growth	+73.62%
Outstanding Shares	2.58M

Technical Indicators

50-Day SMA	$3.00
200-Day SMA	$3.90
RSI (14)	66.12
Beta	1.31
52-Week High	$10.70
52-Week Low	$1.31

Volume Today	15.76K
Avg Daily Volume (30D)	14.56K
Relative Volume	1.08x
Volatility (10D)	148.20
Volatility (30D)	94.69
Free Float	95.32%

Analyst Consensus

BUY

Current Price $3.98

Mean Target $8.33

52W Low$1.31 52W High$10.70

Current

Target

$1.31 $10.70

Current Analyst target

+109.38% upside potential · 4 analysts

Identifiers

ExchangeNasdaq

FIGIBBG00HNGDTS3

ISINUS00688A3041

CountryUnited States of America

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateAug 13, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LONN.S Lonza Group AG -1.78% RVMD Revolution Medicines Inc +0.85% ONC BeOne Medicines AG -2.40% 068270.KS Celltrion Inc -0.50% ABVX Abivax SA -2.05%

Company Profile

Adial Pharmaceuticals, Inc. is a biopharmaceutical company. Its lead program is AT177, a proprietary colon?targeted aryl hydrocarbon receptor (AhR) agonist designed to enable localized activation with limited systemic exposure in development for ulcerative colitis. AT177 is a fully synthetic, patented, oral AhR agonist designed to restore mucosal immune homeostasis at the site of disease with minimal systemic exposure. AT177's active ingredient is a prodrug of indirubin, a potent AhR agonist within indigo naturalis, a botanical extract with clinical efficacy in ulcerative colitis. AT177's colon-targeted formulation delivers therapeutic AhR engagement directly to the colonic mucosa with exquisite gut restriction, minimizing the systemic AhR exposure associated with adverse effects. Its historical investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder in heavy drinking patients.